Presenting touchONCOLOGY, a comprehensive educational brand that explores cutting-edge research, clinical trials, and developments in the field of oncology. Our brand is committed to providing insightful content and interviews with leading experts in the industry to keep healthcare professionals updated on the latest advancements in cancer treatment.

Our unique Prostate Biomarker (ProBio) study, using outcome-adaptive randomization, has compared biomarker-driven treatment selection against physician’s choice, and pitted androgen receptor inhibitors (ARPIs) against standard-of-care (SOC) and taxanes in castrate-resistant prostate cancer (mCRPC). This innovative study, led by renowned expert Prof. Henrik Grönberg, has produced groundbreaking findings that will influence future treatment decisions for mCRPC.

The ProBio study’s unique methodology, incorporating adaptive randomization and prospective biomarker utilization, has distinguished it from traditional trial designs. The key findings have highlighted the superiority of androgen receptor inhibitors in certain biomarker subtypes, thus shaping a more targeted approach to treatment selection.

touchONCOLOGY is dedicated to providing credible and relevant information to drive better patient outcomes in oncology. Join us as we uncover the latest breakthroughs and discuss their implications for the future of cancer treatment.